Nordic Life Science 1
NORDIC LIFE SCIENCE EDITOR IN CHIEF: MALIN OTMANI
ART DIRECTOR: ANNIKI SKEIDSVOLL EDÉN REPORTERS: ELLEN R. DELISIO, CHRIS TACHIBANA, ANNELI HIDALGO ENGLISH PROOFREADING: GAIL ADAM REPRO: LENA HOXTER COVER PHOTO: NIAID-RML PRINTED BY: ÅTTA.45 2020 PUBLISHING DIRECTOR: MATTIAS OLME PRODUCT MANAGER: ADAM RÅSBERG MARKETING & SALES: ANDRES VARGAS ANDRES@NORDICLIFESCIENCE.ORG +46 8 588 941 56 COPYRIGHT 2020 BY MEDIAVALUE ALL RIGHTS RESERVED. REPRODUCTION IN WHOLE OR IN PART WHITHOUT PERMISSION IS PROHIBITED. A MAGAZINE FROM MEDIAVALUE MV INFORMATION AB, KINDSTUGATAN 1 111 31 STOCKHOLM, SWEDEN PHONE: +46 8 588 941 51 SUBSCRIPTION: ONE YEAR PRINT AND ONLINE SUBSCRIPTION: 1 990 SEK / 199 EUR / 219 USD 01. FOUR PRINTED ISSUES OF THE BUSINESS MAGAZINE 02. ALL ISSUES ONLINE, READABLE ON YOUR PREFERRED DEVICE 03. WEEKLY NEWS UPDATES FROM OUR NEWSLETTER NORDIC LIFE SCIENCE NEWS CALL: +46 8 588 941 52 OR SIGN UP AT: NORDICLIFESCIENCE.ORG have been very severe. As of today, August 27 2020, there are over 24 million global cases and almost 825 798 global deaths, and according to William A. Haseltine, scientist, author and philanthropist, interviewed on page 70, the coronavirus play havoc with our immune system in ways we have never previously seen. The new virus has also left dramatic effects across the global economy as the world’s populations are experiencing reductions in income, a rise in unemployment, and business closures. It has also hurt the life science industry in many ways, including halted clinical trials, bankruptcies and staff reductions. But the pandemic has also forced the life science industry to develop and adapt itself in certain areas. We have for example seen a faster decision-making capacity from governments and global organizations and also an acceleration of collaborations across the healthcare innovation ecosystem. Mikael Dolsten, Chief Scientific Officer at Pfizer, interviewed on page 44, says that the pandemic has created a new sense of openness and trust to share early data and novel ideas, and hopefully, this will influence other areas of global health. Perhaps the next big crisis will be related to antimicrobial resistance, like Arne Flåøyen, Director at NordForsk, interviewed on page 24, suggests. And on a positive note, this summer a historic partnership, the AMR Action Fund, was launched. The pharma industry has come together and committed itself to invest almost 1 billion USD in the Fund, making it the largest joint venture effort aimed to combat antibiotic resistance ever. PARTNERS: The pandemic has also pushed developments within digitalization forward. The vacuum created by the coronavirus has been filled with digital technologies, not just helping us work from home or maintaining contact with each other, but also accelerating progress within AI, 3D printing, advanced robotics, and wearable technologies. There are also examples of digital solutions enabling the progress of clinical trials and maintaining manufacturing capacities. Hopefully, in the wake of the pandemic, we will experience both advancement of new and enabling technologies and concrete cross-border actions – making us better equipped to face all global health issues. MALIN OTMANI EDITOR IN CHIEF FOR DAILY UPDATES OF THE NORDIC LIFE SCIENCE INDUSTRY, VISIT: NORDICLIFESCIENCE.ORG.